{
    "organizations": [],
    "uuid": "b4c7ce6463d037a0798c4f1fd7cd28189602afe1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-announces-p/brief-mithra-pharmaceuticals-announces-positive-donesta-phase-iib-study-idUSFWN1RV0ZJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE\n* STUDY CONCLUDED THAT 15 MG OF E4 WAS OPTIMAL ORAL MINIMUM DOSE FOR EFFECTIVE TREATMENT OF VMS.\n* THIS DOSE COHORT DEMONSTRATES REDUCTION OF OVER 80% IN FREQUENCY OF MODERATE TO SEVERE VMS WHEN COMPARED TO BASELINE. Source text : bit.ly/2qKQ8h7 Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-19T13:56:00.000+03:00",
    "crawled": "2018-04-20T12:12:06.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "mithra",
        "pharmaceutical",
        "sa",
        "announces",
        "positive",
        "donesta",
        "phase",
        "iib",
        "study",
        "achieving",
        "primary",
        "objective",
        "confirming",
        "promising",
        "safety",
        "profile",
        "study",
        "concluded",
        "mg",
        "e4",
        "optimal",
        "oral",
        "minimum",
        "dose",
        "effective",
        "treatment",
        "vms",
        "dose",
        "cohort",
        "demonstrates",
        "reduction",
        "frequency",
        "moderate",
        "severe",
        "vms",
        "compared",
        "baseline",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}